Comparing Diode Laser Vaporization of the Prostate With Photoselective Vaporization of the Prostate for the Treatment of Benign Prostatic Obstruction—Multi-Center, Single-Blind, Non-Inferiority Design Randomized Controlled Trial

Comparing 450nm Diode Laser Vaporization of the Prostate With 532nm Photoselective Vaporization of the Prostate for the Treatment of Benign Prostatic Obstruction—Multi-Center, Single-Blind, Non-Inferiority Design Randomized Controlled Trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032522

Enrollment

Unknown

Registered

2020-05-01

Start date

2020-06-01

Completion date

Unknown

Last updated

2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Interventions

Blue laser (450nm Diode laser):Diode laser vaporization the prostate

Green laser (532nm laser):Photoselective vaporization of the prostate

Eligibility

Sex/Gender

Male

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Male, aged 50-85 years; 2. BPH patients who plan to have surgery; 3. Patients with IPSS score of 8-35; 4. Patients with prostate volume of 30-100ml; 5. The maximum urine flow rate (Qmax) is <= 15ml / S; 6. Patients who are able to complete the relevant scale scores under the guidance of doctors; 7. Patients who voluntarily participate and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with neurocystitis, urethral stricture and cystoscopic sheath failure after transurethral dilatation; 2. Patients diagnosed or suspected of prostate cancer or bladder cancer; 3. Patients with severe cardiovascular and cerebrovascular diseases, severe respiratory diseases and severe liver and kidney dysfunction; 4. Patients who participated in other clinical trials within three months before admission; 5. Other conditions that the researchers think are not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
IPSS;Qmax;Decrease in hemoglobin;	—

Secondary

Measure	Time frame
operative time;Serum electrolyte changes;Time of bladder irrigation;catheterization time;hospital stay days;QOL;IIEF-5;prostate volume;PSA;	—

Countries

China

Contacts

Public ContactChaozhao Liang

The First Affiliated Hospital of Anhui Medical University

qvb119@163.com+86 18010883001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026